Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 221

Similar articles for PubMed (Select 17518359)

1.

Effects of solution conditions and surface chemistry on the adsorption of three recombinant botulinum neurotoxin antigens to aluminum salt adjuvants.

Vessely C, Estey T, Randolph TW, Henderson I, Nayar R, Carpenter JF.

J Pharm Sci. 2007 Sep;96(9):2375-89.

PMID:
17518359
2.

The importance of surface charge in the optimization of antigen-adjuvant interactions.

Callahan PM, Shorter AL, Hem SL.

Pharm Res. 1991 Jul;8(7):851-8.

PMID:
1924135
3.
5.

Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution.

Vessely C, Estey T, Randolph TW, Henderson I, Cooper J, Nayar R, Braun LJ, Carpenter JF.

J Pharm Sci. 2009 Sep;98(9):2970-93. doi: 10.1002/jps.21498.

6.

Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry.

Estey T, Vessely C, Randolph TW, Henderson I, Braun LJ, Nayar R, Carpenter JF.

J Pharm Sci. 2009 Sep;98(9):2994-3012. doi: 10.1002/jps.21543.

7.

Preformulation characterization of an aluminum salt-adjuvanted trivalent recombinant protein-based vaccine candidate against Streptococcus pneumoniae.

Iyer V, Hu L, Liyanage MR, Esfandiary R, Reinisch C, Meinke A, Maisonneuve J, Volkin DB, Joshi SB, Middaugh CR.

J Pharm Sci. 2012 Sep;101(9):3078-90. doi: 10.1002/jps.23175. Epub 2012 Apr 26.

PMID:
22538529
8.

Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants.

Jendrek S, Little SF, Hem S, Mitra G, Giardina S.

Vaccine. 2003 Jun 20;21(21-22):3011-8.

PMID:
12798645
9.

Role of the electrostatic attractive force in the adsorption of proteins by aluminum hydroxide adjuvant.

Chang MF, White JL, Nail SL, Hem SL.

PDA J Pharm Sci Technol. 1997 Jan-Feb;51(1):25-9.

PMID:
9099061
10.

Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants.

Peek LJ, Martin TT, Elk Nation C, Pegram SA, Middaugh CR.

J Pharm Sci. 2007 Mar;96(3):547-57.

PMID:
17080408
11.

Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants.

Berthold I, Pombo ML, Wagner L, Arciniega JL.

Vaccine. 2005 Mar 14;23(16):1993-9.

PMID:
15734073
12.

Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants.

Romero Méndez IZ, Shi Y, HogenEsch H, Hem SL.

Vaccine. 2007 Jan 15;25(5):825-33. Epub 2006 Sep 25.

PMID:
17014935
13.

Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants.

Ljutic B, Ochs M, Messham B, Ming M, Dookie A, Harper K, Ausar SF.

Vaccine. 2012 Apr 19;30(19):2981-8. doi: 10.1016/j.vaccine.2012.02.038. Epub 2012 Feb 27.

PMID:
22381074
14.

Mechanism of adsorption of hepatitis B surface antigen by aluminum hydroxide adjuvant.

Iyer S, Robinett RS, HogenEsch H, Hem SL.

Vaccine. 2004 Mar 29;22(11-12):1475-9.

PMID:
15063571
15.
16.

A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine.

Peek LJ, Brey RN, Middaugh CR.

J Pharm Sci. 2007 Jan;96(1):44-60.

PMID:
16998874
17.

Effect of protein adsorption on the surface charge characteristics of aluminium-containing adjuvants.

al-Shakhshir R, Regnier F, White JL, Hem SL.

Vaccine. 1994 Apr;12(5):472-4.

PMID:
8023556
18.
19.
20.

Detoxification of endotoxin by aluminum hydroxide adjuvant.

Shi Y, HogenEsch H, Regnier FE, Hem SL.

Vaccine. 2001 Feb 8;19(13-14):1747-52.

PMID:
11166900
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk